Trauma From Iraq Could Alter Vetera...(tant professor psychiatry and behavioral...),Health
Navigation Links
Trauma From Iraq Could Alter Veterans' Brains
Date:9/9/2009
tant professor, psychiatry and behavioral sciences, Albert Einstein College of Medicine, and associate director, psychology training, Montefiore Medical Center, New York City; September 2009 Archives of General Psychiatry
'/>"/>
| Copyright©2009 ScoutNews,LLC. All rights reserved |
Related medicine news :
1. Study finds post-traumatic stress symptoms in adolescent children of cancer patients
2. Toxic Shock Drug Might Aid Trauma Victims
3. Center gets national funding for child trauma research
4. Pennsylvania Trauma Systems Foundation Accreditation Status for Trauma Centers
5. Easter Seals Launches Program for Veterans Returning from Iraq and Afghanistan with Traumatic Brain Injuries
6. First Level III Trauma Center Accredited in Pennsylvania
7. Pennsylvania Trauma Center Accreditation Status
8. Value of Most Post-Traumatic Stress Treatments Uncertain
9. California Wildfires - Psychological Effects; Children ... Psychologist Is Available to Discuss Trauma
10. Imaging shows structural changes in mild traumatic brain injury
11. California Association of Marriage & Family Therapists Offers Tips on How to Cope With a Traumatic Event
Post Your Comments:
Related Image:
 Trauma From Iraq Could Alter Veterans' Brains |
(Date:12/2/2009)...rior to pregnancy increased risk by 22% , ...o drink five or more servings of sugar-sweetened c...isk of developing diabetes during pregnancy, a new...n an association with other chronic metabolic prob...ant professor of epidemiology at Louisiana State U...
(Date:12/2/2009)...w Year traditionally inspires making resolutions t...What to do to ensure the energy, and positive outl...It’s easy; make self-care the #1 priority. A...ion. It isn,t any wonder their products excel in t... safe cosmetic products. , ...
(Date:12/2/2009)...ed by Suzanne Somers in her N.Y. Times #1 best-sel... NY (PRWEB) December 2, 2009 -- In her new book KN...cer, And How to Prevent Getting It in the First Pl...cessfully using the most innovative cancer treatme... tear it down. This is a subject Somers writes abo...
(Date:12/2/2009)...vice software engineering consulting firm Full Spe...n. A relatively few medical device software engine...13485 certification. Many medical device makers ha... standards as well. However, it is somewhat rare f...g firm to achieve the rigorous quality standards a...
(Date:12/2/2009)...wswire/ -- Targeted breast ultrasound of suspiciou... reliable and cost-effective alternative to invasi...he findings of two studies presented today at the ...h America (RSNA). ,, "By performing high-qualit...xpensive and avoidable invasive diagnostic procedu...
Breaking Medicine News(10 mins):Health News:Sugary Colas Tied to Gestational Diabetes 2Health News:Sugary Colas Tied to Gestational Diabetes 3Health News:The New Year's Resolution that Fuels Them All: Self-Care; Garden of Eve Makes Self-Care Through Safe Skin Care # 1 Priority 2Health News:The New Year's Resolution that Fuels Them All: Self-Care; Garden of Eve Makes Self-Care Through Safe Skin Care # 1 Priority 3Health News:The New Year's Resolution that Fuels Them All: Self-Care; Garden of Eve Makes Self-Care Through Safe Skin Care # 1 Priority 4Health News:Innovative Biofeedback Technology Wins By A "Knockout." 2Health News:Innovative Biofeedback Technology Wins By A "Knockout." 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 4Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 2[0] Sugary Colas Tied to Gestational Diabetes[0] The New Year's Resolution that Fuels Them All: Self-Care; Garden of Eve Makes Self-Care Through Safe Skin Care # 1 Priority[0] Innovative Biofeedback Technology Wins By A "Knockout." [0] Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification[0] Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty
... GREENWOOD VILLAGE, Colo., May 27 Recondo Technol... for the health care industry, today announced t...North America, designating Recondo as one of the t...: http://www.newscom.com/cgi-bin/prnh/20090325/L...
... Focus on prevention and information can lead to h...nse announced today a partnership with Healthwise(... complement the quality telehealth services it cur...e Response consumers to access over 7,000 health t...
... Titusville, NJ, May 27, 2009 A new instrument f...of long-acting injectable antipsychotic therapy (L...ychiatry 2009. 1 This novel, psychosocial appr...scussion tool. , Nonadherence to oral antipsycho...
... BERKELEY, CA An $18 million, three-year grant t...t breast cancer was awarded today to a multi-insti... that is co-led by Joe Gray, a renowned cancer res...ndustry Foundation charitable organization aimed a...
... Palliative care psychiatrist from The Institute f...DIEGO, May 26 San Diego psychiatrist Scott Irwi...ychiatry Program (PCPP) at The Institute for Palli...ticing psychiatrists nationwide who have demonstra...
... First of its Kind Virtua...fessionals Slated for Tuesday through Thursday Nov...ct Abstracts(at)BioConferenceLive.com , ...healthcare, education and energy markets, and LabR...
Other Medicine News:Health News:Recondo Technology Wins Red Herring 100 North America Award 2Health News:New tool to improve patient understanding of long-acting injectable antipsychotic therapies (LAT) unveiled in April issue of Psychiatry 2009 2Health News:Berkeley Lab scientist co-leads breast cancer 'dream team' 2Health News:Berkeley Lab scientist co-leads breast cancer 'dream team' 3Health News:San Diego Psychiatrist Scott Irwin Honored With National Recognition 2Health News:San Diego Psychiatrist Scott Irwin Honored With National Recognition 3Health News:PlatformQ and LabRoots Announce BioConference Live, Online Conference for the Life Science Research and Laboratory Sciences Community 2Health News:PlatformQ and LabRoots Announce BioConference Live, Online Conference for the Life Science Research and Laboratory Sciences Community 3Recondo Technology Wins Red Herring 100 North America AwardNurse Response Partners With Healthwise to Help Consumers Make Informed Decisions on HealthNew tool to improve patient understanding of long-acting injectable antipsychotic therapies (LAT) unveiled in April issue of Psychiatry 2009Berkeley Lab scientist co-leads breast cancer 'dream team'San Diego Psychiatrist Scott Irwin Honored With National RecognitionPlatformQ and LabRoots Announce BioConference Live, Online Conference for the Life Science Research and Laboratory Sciences Community
(Date:12/2/2009)...c. 2 Roche (SIX: RO, ROG...ates Food & Drug Administration (FDA) approved...ic acid test, to screen source plasma in pools com... called the cobas® TaqScreen MPX Test for use...-vitro test for the simultaneous, direct detection...
(Date:12/2/2009)...N.J., Dec. 2 Novartis announced to...ntation on Tasigna® (nilotinib) 200 mg capsul...ate the strength of the company,s hematology portf... new data, at the 51st American Society of Hematol... the company,s current therapies and investigation...
(Date:12/1/2009)...Dec. 1 Reproductive Partners Medic...ryo Transfer (eSET) Encouragement Program to provi...bryo quality and a good prognosis for success to c...ng a single embryo. ,, The biggest issue in adv...e number of multiple pregnancies, even twin pregna...
Breaking Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2Strep B Seems to Trick Immune System 51448 1InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 1InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 2Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 1Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 2Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 3Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 4[0] FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus[0] Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting[0] Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program
...armaceuticals, Inc. (Nasdaq: RIGL ) announced tod... 1 study to evaluate the safety and,tolerability o...anus Kinase,3 (JAK3), as a potential treatment for...s and other immune disorders. In preclinical studi...hritic symptoms, bone destruction,and swelling. It...
...omach. Whatever illness it is, it can make you fee...ther but it is even more difficult to handle,being...rican Diabetes Association (ADA), people with,diab...s complications if,they don,t take care of their d...ease to dangerous levels if left unchecked. Ketone...
Other Medicine Technology:Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 2Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 3Help! I'm Sick. How Do I Handle My Diabetes? 2...nds life of lamp Reserve lamp at the flip of a lev... reserve lamp in primary port Thermostatically co... electrical certification Lamp out indicator lets...p for quick replacement. Mobile five-caster stand ...
TrueView Classic
High Beam Sport
...mistry Analyzer is a semi-automated benchtop instr... The UrinQuick is designed to analyze and generate... UrinChek 8+ urine test strips. The UrinQuick anal...hotometry. Test results are available in conventio...
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |